OR WAIT 15 SECS
The company has broken ground on a R&D and process development facility in Missouri.
On June 27, 2017, Pfizer announced that it has broken ground on a new R&D and process development facility in Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work across multiple locations. Pfizer said it expects to hire an additional 80 employees to support research at the Chesterfield facility. Construction is expected to be complete by 2019.
The facility will provide approximately 295,000 ft2 of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying analytical technologies, conducting non-GMP manufacturing, and scale-up studies. According to Pfizer, this work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation and immunology, and vaccines, including biosimilars.
The campus will include a floorplan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces, and increased conferencing technologies where researchers can collaborate. As part of the strategic incentives package from St. Louis County and the State of Missouri, Pfizer is donating $20,000 to the local Parkway School District to support STEM education.